New Sizes Will Allow Physicians to Treat Broader Group of Patients with Bifurcation Disease

Durham, N.C. – Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced receipt of CE Mark for  larger-diameter sizes of the Tryton Side Branch Stent System™ for the treatment of coronary artery disease.  Launch of the larger diameter size stents, 3.0 to 3.5mm and 3.5 to 4.0mm, has begun in Europe.  The new sizes are designed for larger coronary vessels.  

“Current treatments for bifurcations have significant limitations, including higher rates of thrombosis – potentially fatal blood clots – and restenosis,” said Prof. Robert Van Geuns, associate professor, Erasmus Medical Center, Rotterdam, The Netherlands.  “Tryton’s Side Branch Stent System is an innovative solution to this persistent problem with impressive acute and long-term clinical outcomes.  I am pleased that the launch of larger sizes of the Tryton Stent System will enable me to treat additional patients with bifurcations disease.”

“With nearly 3,000 patients now treated and our randomized, multi-center pivotal trial enrolling patients in the United States, we continue to see positive momentum for the Tryton Side Branch Stent System,” said Rick Anderson, board member of Tryton and managing director of PTV Sciences.  “We are pleased that we have been able to respond to physicians’ requests for larger-diameter sizes of the device, enabling them to treat a larger portion of their patients with bifurcation disease.”

Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another.  Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation.  Bifurcation lesions account for as many as one-third of all coronary lesions.

Source: Tryton Medical, Inc.